Mini Review ARTICLE
Clinical and Genetic Factors to Inform Reducing Colorectal Cancer Disparitites in African Americans
- Division of Gastroenterology, Departments of Internal Medicine and Human Genetics, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, United States
Colorectal cancer (CRC) is the third most prevalent and second deadliest cancer in the U.S. with 140,250 cases and 50,630 deaths for 2018. Prevention of CRC through screening is effective. Among categorized races in the U.S., African Americans (AAs) show the highest incidence and death rates per 100,000 when compared to Non-Hispanic Whites (NHWs), American Indian/Alaskan Natives, Hispanics, and Asian/Pacific Islanders, with an overall AA:NHW ratio of 1.13 for incidence and 1.32 for mortality (2010-2014, seer.cancer.gov). The disparity for CRC incidence and worsened mortality among AAs is likely multifactorial and includes environmental (e.g., diet and intestinal microbiome composition, prevalence of obesity, use of aspirin, alcohol, and tobacco use), societal (e.g., socioeconomic status, insurance and access to care, and screening uptake and behaviors), and genetic (e.g., somatic driver mutations, race-specific variants in genes, and inflammation and immunological factors). Some of these parameters have been investigated, and interventions that address specific parameters have proven to be effective in lowering the disparity. For instance, there is strong evidence raising screening utilization rates among AAs to that of NHWs reduces CRC incidence to that of NHWs. Reducing the age to commence CRC screening in AA patients may further address incidence disparity, due to the earlier age onset of CRC. Identified genetic and epigenetic changes such as reduced MLH1 hypermethylation frequency, presence of inflammation-associated microsatellite alterations, and unique driver gene mutations (FLCN and EPHA6) among AA CRCs will afford more precise approaches toward CRC care, including the use of 5-fluorouracil and anti-PD-1.
Colorectal cancer (CRC) is common in the U.S. It is the third most prevalent cancer (behind lung and prostate in men and behind lung and breast in women), but the second most deadliest cancer in both men and women (1). Among categorized races and ethnic groups in the U.S., African Americans (AAs) demonstrate the highest incidence among males and females for CRC (56.4 and 41.7 per 100,000 population, respectively) and the highest mortality among males and females (25.1 and 16.5 per 100,000 population) over Caucasians, Asians, Hispanics, and American Indian/Alaskan Natives. The incidence and mortality among AAs compare unfavorably to the U.S. general population, where rates for incidence are 45.9 and 34.8 per 100,000 and rates for mortality are 17.3 and 12.2 per 100,000 population (1). The ratio for CRC incidence between AAs and Non-Hispanic Whites (NHW) is 1.13, meaning that for every 100 CRCs in NHWs, there are 113 CRCs in AAs (2). This disparity in incidence is further amplified when one examines CRC mortality, with the AA:NHW mortality ratio of 1.32, meaning that for every 100 CRC deaths in NHWs, there are 132 deaths in AAs (2). Recent data regarding the observed increase of CRC among young patients (< 50 years of age) suggests that the disparity begins early for AAs with rates for CRC incidence at 7.9 per 100,000, compared to NHWs and Asians of 6.7 and 6.3 per 100,000, respectively, among patients aged 20–44 (3, 4). It should be noted that the overall trends for CRC death have decreased for both AAs and NHWs since the 1990s; however, for males, the decrement has been faster for NHWs than AAs increasing the disparity, whereas for females the decrement in CRC mortality has be roughly equivalent for NHWs and AAs, maintaining a constant but stable mortality disparity (5). AAs tend to present with less localized and regional staged CRC and more distant staged CRC when compared to Caucasians (localized 38 vs. 39%, regional 32 vs. 36%, distant 25 vs. 21%) (1). Furthermore, AAs with CRC show an overall survival rate for all stages of 58% at 5 years compared to 66% for Caucasians. When further broken down, AAs show reduced survival than Caucasians at all stages (localized 86 vs. 90%, regional 65 vs. 72%, distant 10 vs. 14%) (1).
Why is there a disparity in CRC incidence and mortality for AAs? The answer is likely multifactorial. There are a number of modifiable and non-modifiable factors that can change the risk of developing and dying from CRC, with some adversely affecting risk and some reducing risk. Modifiable risks include: diet and intestinal microbiome composition, socioeconomic factors, screening utilization rates, healthcare access, education level, physical activity, use of tobacco products, use of alcohol, and use of aspirin/NSAIDs and hormonal replacement therapy, among others (6, 7). The modifiable risks have been shown to influence CRC incidence at the epidemiological and individual levels, with some measures that change modifiable risks hard to implement consistently in individuals among various populations. Non-modifiable risks include: age, family history, and racial background (6). These non-modifiable risks infer genetic causes as part of the driver for CRC risk. In particular, age is a strong predictor for the development of adenomas, a precursor of CRC, and CRC itself (6). There is a near exponential rise in CRC in the U.S. population around age 50 years (and thus this age was selected to commence CRC screening in average risk individuals), with 94.5% of all CRCs occuring after this age and 5.5% occuring younger than age 50 years (8). For AAs, the CRC rate curve is shifted to earlier ages (6, 9–12) such that the proportion of CRCs are doubled under the age of 50 years compared to Caucasians (10.6 vs. 5.5%) (Figure 1). With screening commencing at age 45 years for AAs (13), the proportion of CRCs under age 45 is the same proportion of CRCs for Caucasians starting screening at age 50 years (Figure 1) (6).
Figure 1. (Left) Rates per 100,000 of colorectal cancer for Caucasians and African Americans by age group. (Right) Proportion of colorectal cancers under and over targeted ages for screening for Caucasians and African Americans.
For most CRCs, adenomas are the direct precursor (14, 15). Thus, with an increased rate of CRC among AAs, there should be some evidence of increased adenomas, and indeed there is. Lieberman et al. reported the prevalence of high risk adenomas (those >9 mm in diameter), in AAs (7.7%) and Caucasians (6.2%) among 85,000 individual colonoscopies (16). In a follow-up study of 327,785 average risk adults, both male and female AA patients demonstrated higher ratios of high risk adenomas for nearly all 5-year age subgroups (e.g., 50–54, 55–59 years, etc.) that increased with age (17). To match the observed 7–15% higher proximal distribution of CRCs among AAs compared to Caucasians (6), proximal high risk adenomas are more prevalent among AAs than Caucasians, with odds ratios of 1.26 (18) and 1.15 (17) in two separate studies that became significant after the age of 60 years. This higher prevalence of adenomas proximal to the colonic splenic flexure in AAs likely contributes to the disparity because colonoscopy, the gold standard tool for screening in the U.S., is not as effective in reducing mortality from right-sided lesions (19–21). The combination of a proximal, harder-to-detect lesions coupled with reduced ability to detect right-sided lesions with any screening test amplify the magnitude of the disparity (6). At present, there is no evidence that there is increased prevalence of high risk sessile serrated adenomas in AAs compared with Caucasians (0.3 vs. 0.2% of colonic lesions, p = 0.71) as a component of the increased right-sided lesions (22).
Below, we explore some specific additional modifiable and non-modifiable risks that may inform approaches to reduce the CRC disparity among AAs. Some of these risk parameters have been investigated, and some interventions that address specific parameters have proven to be effective in lowering the disparity. Others may lead to more precise approaches toward CRC prevention and care.
There is growing evidence that diet and gut microbiome composition greatly influence adenoma and CRC risk (6, 23, 24); however, the data is scant with regards to specific racial differences. Sulfidogenic bacteria produce hydrogen sulfide, which triggers pro-inflammatory pathways and hyperproliferation, was shown more abundant among AA CRC patients from uninvolved colon biopsies compared to NHW CRC patients (25). Proinflammatory Fusobacterium nucleatum and Enterobacter species were found significantly higher among AAs as compared to NHWs at screening colonoscopy, with AAs demonstrating decreased microbial diversity (26). O'Keefe et al. explored 2-week food swaps with before and after colonic mucosa biopsies in AAs and rural Africans, whose diet typically contained a high-fat and low-fiber Western-style diet (AAs) vs. a high-fiber, low-fat African-style diet (rural Africans) (27). Compared to mucosal biopsies before the diet exchange, post-diet swap biopsies showed reciprocal changes in biomarkers. In particular, AAs after 2 weeks of the African-style diet lowered the proliferation marker Ki67 by 50%, whereas rural Africans after the Western-style diet nearly doubled colonocyte proliferation. Furthermore, AAs showed reduced intraepithelial lymphocytes after the African-style diet, whereas rural Africans on the Western-style diet increased inflammation. The short chain fatty acid butyrate, a normal fuel molecule for healthy colonocytes that is made by gut microbes, increased in the colons of AAs on the African-style diet whereas the secondary bile acid deoxycholic acid, which may be a carcinogenic compound, decreased. The opposite happened in the rural Africans' colons after 2 weeks of the Western-style diet, with decreased butyrate levels but increased deoxycholate levels (27). These observations strongly suggest that even short-term diet manipulation can modify colonic contents and colonocyte proliferation parameters that may influence risk for CRC. Extrapolation for prolonged Western diet exposure matches epidemiological evidence for this type of diet and strong association with CRC development. The implications by the O'Keefe et al. data indicate that even higher risk populations for CRC such as AAs might be able to reduce that risk with diet manipulation. This would likely require a lifestyle change that is sustained over long periods of time (years) to observe the risk reduction.
Inherited germline adenomatous polyposis syndromes such as familial adenomatous polyposis, MYH-associated polyposis, polymerase proofreading associated polyposis, Lynch syndrome, and Familial Colorectal Cancer Type X seem to exist in multiple racial and ethnic populations including AAs, but there is no evidence for a predilection for AAs for any of these syndromes (9, 28). Guindalini et al. examined AA Lynch syndrome families, and showed that two-thirds of the families contained a germline mutation in the DNA mismatch repair gene MLH1, with a cumulative cancer risk similar to those from European descent (29). However, multiple novel mutations within MLH1 were discovered in AAs that were not demonstrated in national mutational databases, suggesting genetic diversity of the mutational spectrum of MLH1.
Somatic mutations of key cell regulatory genes to inactivate their growth regulatory abilities are a defining property of sporadic CRCs. CRCs can be segregated into hypermutated tumors (with hundreds to thousands of accumulated mutations) that are the result of failed DNA mismatch repair (typically by hypermethylation of MLH1) or mutation in the POLE gene that encodes polymerase ε, and non-hypermutated tumors (with 1–8 accumulated driver mutations) (30). While each individual's CRC has an overall unique mutational profile (15), common to hypermutated CRCs are a spectrum of accumulated somatic mutations that are largely the result of frameshift mutations in genes with coding microsatellites, such as ACVR2, TGFBR2, MSH3, and MSH6, along with BRAF mutations (30). Non-hypermutated CRCs commonly demonstrate mutations in APC, TP53, KRAS, TTN, and PIK3CA (30). This large and defining dataset could not determine any racial differences in gene mutations due to the paucity of AA CRCs examined (< 5 of 224 primary CRCs) (30).
Guda et al. (31) sequenced 103 AA and 129 Caucasian CRCs to identify any AA-specific somatic driver mutations. Three genes were found exclusively mutated in CRCs from AAs: EPHA6 (mutational frequency of 5.83% in AAs, 0% in Caucasians), FLCN (mutational frequency of 2.91% in AAs, 0% in Caucasians), and HTR1F (mutational frequency of 2.91% in AAs, 0% in Caucasians) (31). Further examination of mutations in EPHA6 showed missense and splice site mutations, and mutations in FLCN were frameshift insertions and non-sense mutations, identifiying most of the discovered mutations as deleterious (31). These exclusive mutations among AA tumors raise the possibility that EPHA6 and FLCN are unique driver genes in this population, but it remains to be determined if these mutated genes in any way contribute toward the incidence or mortality disparity observed.
Inactivation of the DNA mismatch repair gene MLH1 is the (epi)genetic cause for most hypermutated CRCs. Hypermutated tumors are more often located in the proximal colon, demonstrate microsatellite instability (or MSI-High, a biomarker for ongoing frameshift mutation), and demonstrate lymphoid aggregates and increased intraepithelial lymphocytes within the CRC as a reaction to immunologically-driven frameshifted neoantigen proteins (15, 32). Patients with hypermutated tumors demonstrate longer survival as compared to patients with non-hypermutated tumors (15, 33) without any treatment, and further demonstrate improved survival with immune checkpoint inhibitor therapy (34, 35). Patients with hypermutated tumors also respond less to standardized 5-fluorouracil-containing therapy (5-FU), as DNA mismatch repair is one mechanism to execute the toxicity of 5-FU (36–43). In a population-based study, the proportion of Caucasian CRCs that demonstrated MSI-High (hypermutated) was 14 vs. 7% among AA CRCs (44). A meta-analysis of the few MSI-High studies that identified race in cohorts calculated an odds ratio of 0.78 for AA CRCs to demonstrate MSI-H as compared to Caucasian CRCs, but with few studies available did not reach a statistical significance (45). The apparent lower hypermutated CRC prevalence among AAs may contribute to decreased survival as a group, and may further limit the use of immune checkpoint inhibitors that could prolong survival. Lowered MSI-High prevalence among AAs might also mean a higher proportion may respond to 5-FU treatment.
Another mechanism to inactivate DNA mismatch repair somatically is through inflammatory pathways. Tseng-Rogenski et al. demonstrated that oxidative stress and IL-6, both released when inflammation is present, shifts the DNA MMR gene MSH3 from the nucleus where it repairs DNA to the cytosol, where it cannot repair DNA (46, 47). MSH3 normally hetrodimerizes with MSH2 to form MutSβ that repairs slippage at DNA microsattelite repeats that contain two (di), three (tri), or four (tetra) or more nucleotides (33, 48). When MutSβ becomes non-functional with the subcellular shift of MSH3, microsatellite slippage mutations accumulate and can be detected as “elevated microsatellite alterations at selected tetranucleotide repeats” or EMAST. CRCs manifesting EMAST tend to have intratumoral and intraepithelial inflammation (showing intimate association between immune cells and EMAST), be staged as advanced cancers with higher frequency of metastases, and patients show poor survival (49–52). Devaraj et al. showed that 49% of AA rectal cancers demonstrated EMAST as compared to 26% of Caucasian rectal cancers (53), linking this aggressive-associated biomarker as a potential contributor to the disparity. Lowering inflammation may be a possible avenue to reduce these inflammatory-associated microsatellite alterations and possibly improve outcome (54).
Immune cells play key roles in cancer pathogenesis and patient outcome (55). Galon et al. showed that high levels of lymphocytes at the center and invasive margin of the tumor irrespective of stage was associated with improved patient survival compared to those patients with low levels of lymphocytes (56). These lymphocytes were mainly CD8+ and granzyme B+ cytotoxic T lymphocytes, as well as CD45RO+ memory cells (57). MSI-High CRCs induce inflammation by generation of expressed peptides from frameshifted genes that are recognized as neoantigens by the immune system (15, 32) and induce memory T cell differentiation with tumor cells acquiring PD-1 receptors (57); however, it is the CD8+/CD45RO+ T cell immune response irrespective of being an MSI-High or microsatellite stable (MSS) tumor that may be a more over-riding determinant of patient outcome (57). Patients with MSI-High tumors no matter their organ origin are now eligible for anti-PD-1 therapy as approved by the U.S. Food and Drug Administration (35).
The lower frequency of MSI-High among AA CRC patients means that as a group, there will likely be less benefit from anti-PD-1 therapy (44). Although the number of CD8+ T cells are demonstrated higher among MSI-High CRCs, AA MSI-High and AA MSS CRCs lack high counts of CD8+ T cells as compared to Caucasian MSI-High and MSS CRCs (44). In a study involving 250 CRCs, Basa et al. showed reduced intraepithelial and intra-tumoral granzyme B+ T cells among AA MSS CRCs as compared to Caucasian MSS CRCs (58). These observations of lower CD8+ and granzyme B+ T cells among AA CRCs implicate less immune cytotoxicity for tumor cells as a potential contributor to poor outcome and the observed disparity.
CRC Screening is effective in reducing morbidity and mortality from CRC, and is highly cost effective (6). There have been several proposed strategies to reduce the disparity for CRC in AAs with all of them relying on improved prevention (59). Patient education might address patient-level barriers for CRC screening, but there are challenges in the ability to effectively reach all target populations. Physician education might address the lower rates of physician recommendation for screening in AAs, but there is no data on effectiveness of this strategy as well as issues of the target physician population (e.g., gastroenterologists, primary care physicians, etc.). Patient navigation provides strong evidence for increasing CRC screening rates for AAs and is cost-effective. However, this requires training and implementation, and there are barriers to cost and insurance coverage. Another strategy is to lower the age for screening (see Figure 1) as recommended by the U.S. Multi-Society Task Force on Colorectal Cancer to 45 years of age (13). This approach should reduce the burden of early disease, but there has been no prospective study on its effectiveness (59). However, this is the first time race is considered in these nationally-influential multi-society guidelines.
There is strong evidence that increasing CRC screening reduces the disparity for AAs (as well as reduce the overall incidence of CRC). The Delaware Cancer Consortium performed 10,000 patient navigations for colonoscopic CRC screening among AAs and Caucasians between 2001 and 2009 (60). The stage at diagnosis for AA CRC patients change dramatically between 2001 and 2009 with the intervention of navigated CRC screening, with distant disease dropping from 23 to 7%, regional disease dropping from 56 to 33%, and local disease (potentially curable) rising from 15 to 50% (60). Additionally, as the number of navigated patients screened increased (AA: 47.8 to 73.5%; Caucasians: 58.0 to 74.7%), the CRC incidence dropped as the study progressed for both AAs and Caucasians, with the AA rate falling from 68 to 48 per 100,000, and Caucasians falling from 60 to 48 per 100,000 (60). This means the disparity in CRC incidence that existed at the beginning of the study was no longer by the end of the study. Similarly, CRC mortality was reduced over the course of the study for AA CRC patients, dropping from 31.27 to 18.35 per 100,000, and Caucasians dropped from 19.45 to 16.94 per 100,000 (60). The AA CRC mortality closed a large gap disparity such that by the end of the study, the rate approximated that observed for Caucasians. These data strongly suggest that increasing the rate of CRC screening overall for a population can reduce disparity.
Summary and the Future
There is disparity in CRC incidence and mortality for AAs that likely has multifactorial causes. AAs present with earlier onset, higher proportion of proximal, and higher proportion of young CRC. Similarily, AAs show higher proportions of advanced and proximal adenomas, the precursors to CRC. Westernized diets lowers short chain fatty acids and increases secondary bile acids, and is a likely a contributor. Somatic genetic biomarkers such as lower frequency of MSI-High and higher frequency of EMAST, and potentially unique driver genes such as FLCN and EPHA6 may play a role for the disparity among AA CRC patients. Impaired immune response via lower CD8+ and/or granzyme B+ T cells to control tumor growth or spread may also contribute (see Table 1). Prevention through CRC screening is a key component to reduce the disparity.
There is great possibility of other modifiable and non-modifiable causes of CRC can be manipulated to reduce CRC disparity for incidence or mortality among AAs. An understanding will be enhanced through collection of racially diverse biorepository materials and increased participation in clincial trials for CRC prevention and treatment. Some interesting questions that arise include: (1) what is the effectiveness of screening AAs beginning at the age of 45 years? (2) why do advanced adenomas present earlier in AAs? (3) why do AAs possess more right-sided adenomas (and CRCs)? (4) are there other somatic genetic differences? (5) what if anything might suppress immune function within AA CRCs? Strategies to answer these and other questions can further address the disparity among AA CRCs (61).
The author confirms being the sole contributor of this work and has approved it for publication.
Conflict of Interest Statement
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
This work was supported by the United States Public Health Service (R01 CA206010) and the A. Alfred Taubman Medical Research Institute of the University of Michigan.
MSI-High, microsatellite instability-high; MSS, microsatellite stable; EMAST, elevated microsatellelite alterations at selected tetranucleotide repeats; MMR, DNA mismatch repair; CRC, colorectal cancer; AA, African American; SEER, surveillance, epidemiology, and end results program; NSAID, non-steroidal anti-inflammatory drug; HRT, hormone replacement therapy.
3. Ashktorab H, Vilmenay K, Brim H, Laiyemo AO, Kibreab A, Nouraie M. Colorectal cancer in young African Americans: is it time to revisit guidelines and prevention? Dig Dis Sci. (2016) 61:3026–30. 10.1007/s10620-016-4207-1
5. DeSantis CE, Siegel RL, Sauer AG, Miller KD, Gedewa SA, Alcaraz KI, et al. Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. CA Cancer J Clin. (2016) 66:290–308. 10.3322/caac.21340
8. Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology (1997) 112:594–642. 10.1053/gast.1997.v112.agast970594
12. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA., Inadomi JM, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009. Am J Gastroenterol. (2009) 104:739–50. 10.1038/ajg.2009.104
13. Rex DK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology (2017) 153:307–23. 10.1053/j.gastro.2017.05.013
16. Lieberman DA, Holub JL, Moravec MD, Eisen GM, Peters D, Morris CD. Prevalence of colon polyps detected by colonoscopy screening in asymptomatic black and white patients. JAMA (2008) 300:1417–22. 10.1001/jama.300.12.1417
17. Lieberman DA, Williams JL, Holub JL, Morris CD, Logan JR, Eisen GM, et al. Race, ethnicity, and sex affect risk for polyps >9 mm in average-risk individuals. Gastroenterology (2014) 147:351–8. 10.1053/j.gastro.2014.04.037
18. Corley DA, Jensen CD, Marks AR, Zhao WK, de Boer J, Levin TR, et al. Variation of adenoma prevalence by age, sex, race, and colon location in a large population: implications for screening and quality programs. Clin Gastroenterol Hepatol. (2013) 11:172–80. 10.1016/j.cgh.2012.09.010
19. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. Ann Intern Med. (2009) 150:1–8. 10.7326/0003-4819-150-1-200901060-00306
20. Brenner H, Chang-Claude J, Seiler CM, Rickert A, Hoffmeister M. Protection from colorectal cancer after colonoscopy: a population based, case-control study. Ann Intern Med. (2011) 154:22–30. 10.7326/0003-4819-154-1-201101040-00004
21. Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, et al. Long-term colorectal cancer incidence and mortality after lower endoscopy. N Engl J Med. (2013) 369:1095–105. 10.1056/NEJMoa1301969
22. Schroy PC III, Coe A, Chen CA, O'Brien MJ, Heeren TC. Prevalence of advanced colorectal neoplasia in white and black patients undergoing screening colonoscopy in a safety-net hospital. Ann Intern Med. (2013) 159:13–20. 10.7326/0003-4819-159-1-201307020-00004
23. Dejea CM, Fathi P, Craig JM, Boleij A, Taddese R, Geis AL, et al. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science (2018) 359:592–7. 10.1126/science.aah3648
24. Dejea CM, Wick EC, Hechenbleikner EM, White JR, Mark Welch JL, Rossetti BJ, et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci USA. (2014) 111:18321–6. 10.1073/pnas.1406199111
26. Farhana L, Antaki F, Murshed F, Mahmud H, Judd SL, Nangia-Makker P, et al. Gut microbiome profiling and colorectal cancer in African Americans and Caucasian Americans. World J Gastrointest Pathophysiol. (2018) 9:47–58. 10.4291/wjgp.v9.i2.47
29. Guindalini RS, Win AK, Gulden C, Lindor NM, Newcomb PA, Haile RW, et al. Mutation spectrum and risk of colorectal cancer in African American families with Lynch syndrome. Gastroenterology (2015) 149:1446–53. 10.1053/j.gastro.2015.07.052
31. Guda K, Veigl ML, Varadan V, Nosrati A, Ravi L, Lutterbaugh J, et al. Novel recurrently mutated genes in African American colon cancers. Proc Natl Acad Sci USA. (2015) 112:1149–54. 10.1073/pnas.1417064112
32. Schwitalle Y, Kloor M, Eiermann S, Linnebacher M, Kienle P, Knaebel HP, et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology (2008) 134:988–97. 10.1053/j.gastro.2008.01.015
33. Carethers JM. Hereditary, sporadic and metastatic colorectal cancers are commonly driven by specific spectrums of defective DNA mismatch repair components. Trans Am Clin Climatol Assoc. (2016) 127:81–97.
35. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science (2017) 357:409–13. 10.1126/science.aan6733
36. Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology (1999) 117: 123–31. 10.1016/S0016-5085(99)70558-5
37. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. (2003) 349:247–57. 10.1056/NEJMoa022289
38. Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, et al. Use of 5-fluorouracil and survival in patients with microsatellite unstable colorectal cancer. Gastroenterology (2004) 126: 394–401. 10.1053/j.gastro.2003.12.023
39. Tajima A, Hess MT, Cabrera BL, Kolodner RD, Carethers JM. The mismatch repair complex hMutSα recognizes 5-fluoruracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology (2004) 127:1678–84. 10.1053/j.gastro.2004.10.001
40. Iwaizumi M, Tseng-Rogenski S, Carethers JM. DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells. Cancer Biol Ther. (2011) 12:756–64. 10.4161/cbt.12.8.17169
41. Tajima A, Iwaizumi M, Tseng-Rogenski S, Cabrera BL, Carethers JM. Both hMutSα and hMutSβ complexes participate in 5-fluoruracil cytotoxicity. PLoS ONE (2011) 6:e28117. 10.1371/journal.pone.0028117
42. Suzuki S, Iwaizumi M, Tseng-Rogenski S, Hamaya Y, Miyajima H, Kanaoka S, et al. Production of truncated MBD4 protein by frameshift mutation in DNA mismatch repair-deficient cells enhances 5-fluorouracil sensitivity that is independent of hMLH1 status. Cancer Biol Ther. (2016) 17:760–80. 10.1080/15384047.2016.1178430
43. Suzuki S, Iwaizumi M, Yamada H, Hamaya Y, Furuta T, Kanaoka S, et al. MBD4 frameshift mutation caused by DNA mismatch repair deficiency enhances cytotoxicity by trifluridine, and active antitumor agent of TAS-102, in colorectal cancer cells. Oncotarget (2018) 9:11477–88. 10.18632/oncotarget.22484
44. Carethers JM, Murali B, Yang B, Doctolero RT, Tajima A, Basa R, et al. Influence of race on microsatellite instability and CD8+ T cell infiltration in colon cancer. PLoS ONE (2014) 9:e100461. 10.1371/journal.pone.0100461
46. Tseng-Rogenski S, Chung H, Wilk MB, Zhang S, Iwaizumi M, Carethers JM. Oxidative stress induces nuclear-to-cytosol shift of hMSH3, a potential mechanism for EMAST in colorectal cancer cells. PLoS ONE (2012) 7:e50616. 10.1371/journal.pone.0050616
47. Tseng-Rogenski S, Hamaya Y, Choi D, Carethers JM. Interleukin 6 alters localization of hMSH3, leading to DNA mismatch repair defects in colorectal cancer cells. Gastroenterology (2015) 148:579–89. 10.1053/j.gastro.2014.11.027
49. Carethers JM, Koi M, Tseng-Rogenski S. EMAST is a form of microsatellite instability that is initiated by inflammation and modulates colorectal cancer progression. Genes (2015) 6:185–205. 10.3390/genes6020185
50. Lee S-Y, Chung H, Devaraj B, Iwaizumi M, Han HS, Hwang D-Y, et al. Elevated microsatellite alterations at selected tetranucleotide repeats are associated with morphologies of colorectal neoplasia. Gastroenterology (2010) 139:1519–25. 10.1053/j.gastro.2010.08.001
51. Lee S-Y, Miyai K, Han HS, Hwang D-Y, Seong MK, Chung H, et al. Microsatellite instability, EMAST, and morphology associations with T cell infiltration in colorectal neoplasia. Dig Dis Sci. (2012) 57:72–8. 10.1007/s10620-011-1825-5
52. Hamaya Y, Guarinos C, Tseng-Rogenski SS, Iwaizumi M, Das R, Jover R, et al. Efficacy of 5-fluorouracil adjuvant therapy for patients with EMAST-positive stage II/III colorectal cancers. PLoS ONE (2015) 10:e0127591. 10.1371/journal.pone.0127591
53. Devaraj B, Lee A, Cabrera BL, Miyai K, Luo L, Ramamoorthy S, et al. Relationship of EMAST and microsatellite instability among patients with rectal cancer. J Gastrointest Surg. (2010) 14:1521–8. 10.1007/s11605-010-1340-6
54. Koi M, Tseng-Rogenski SS, Carethers JM. Inflammation-associated microsatellite alterations: mechanisms and significance in the prognosis of patients with colorectal cancer. World J Gastrointest Oncol. (2018) 10:1–14. 10.4251/wjgo.v10.i1.1
56. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 313:1960–4. 10.1126/science.1129139
57. Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity (2016) 44:698–711. 10.1016/j.immuni.2016.02.025
58. Basa RCB, Davies V, Li X, Murali B, Shah J, Yang B, et al. Decreased anti-tumor cytotoxic immunity among colon cancers from African Americans. PLoS ONE (2016) 11:e0156660. 10.1371/journal.pone.0156660
60. Grubbs SS, Polite BN, Carney J Jr, Bowser W, Rogers J, Katurakes N, et al. Eliminating racial disparities in colorectal cancer in the real world: it took a village. J Clin Oncol. (2013) 31:1928–30. 10.1200/JCO.2012.47.8412
61. Polite BN, Adams-Campbell LL, Brawley OW, Bickell N, Carethers JM, Flowers CR, et al. Charting the future of cancer health disparities research: a position statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. Cancer Res. (2017) 77:4548–55 10.1158/0008-5472.CAN-17-0623
Keywords: colorectal cancer, African American, cancer disparity, colon cancer prevention, colon cancer risk, colon cancer genetics, colon cancer immunology, colon cancer survival
Citation: Carethers JM (2018) Clinical and Genetic Factors to Inform Reducing Colorectal Cancer Disparitites in African Americans. Front. Oncol. 8:531. doi: 10.3389/fonc.2018.00531
Received: 21 August 2018; Accepted: 30 October 2018;
Published: 20 November 2018.
Edited by:Thelma Hurd, The University of Texas Health Science Center at San Antonio, United States
Reviewed by:Nathan Ellis, University of Arizona, United States
Paul Willemsen, Ziekenhuisnetwerk Antwerpen Middelheim, Belgium
Copyright © 2018 Carethers. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: John M. Carethers, email@example.com